Simrat Randhawa's most recent trade in Dianthus Therapeutics Inc was a trade of 16,943 Common Stock done at an average price of $90.7 . Disclosure was reported to the exchange on June 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 90.72 per share. | 01 Jun 2026 | 16,943 | 8,159 | - | 90.7 | 1,537,069 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 9,375 | 96,875 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 01 Jun 2026 | 9,375 | 30,530 | - | 22.1 | 206,906 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 6,908 | 64,276 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 01 Jun 2026 | 6,908 | 14,906 | - | 17.9 | 123,515 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 6,249 | 47,925 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 01 Jun 2026 | 6,249 | 21,155 | - | 21.8 | 136,041 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 89.72 per share. | 01 Jun 2026 | 5,428 | 25,102 | - | 89.7 | 487,000 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 91.37 per share. | 01 Jun 2026 | 4,159 | 4,000 | - | 91.4 | 380,008 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 01 Jun 2026 | 3,998 | 7,998 | - | 8.4 | 33,743 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 3,998 | 0 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 81.48 per share. | 12 Mar 2026 | 33,830 | 0 | - | 81.5 | 2,756,468 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 12,500 | 106,250 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 12 Mar 2026 | 12,500 | 33,830 | - | 22.1 | 275,875 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 8,332 | 54,174 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 12 Mar 2026 | 8,332 | 21,330 | - | 21.8 | 181,388 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 7,998 | 3,998 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 12 Mar 2026 | 7,998 | 7,998 | - | 8.4 | 67,503 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 5,000 | 71,184 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 12 Mar 2026 | 5,000 | 12,998 | - | 17.9 | 89,400 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 13 Nov 2025 | 109,031 | 4,000 | - | 38.1 | 4,158,442 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 13 Nov 2025 | 83,978 | 87,978 | - | 8.4 | 708,774 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 83,978 | 11,996 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 37.04 per share. | 13 Nov 2025 | 42,765 | 22,576 | - | 37.0 | 1,584,016 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 40,287 | 76,184 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 13 Nov 2025 | 40,287 | 44,287 | - | 17.9 | 720,332 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 37,494 | 62,506 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.77 per share. | 13 Nov 2025 | 37,494 | 81,781 | - | 21.8 | 816,244 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 31,250 | 118,750 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.07 per share. | 13 Nov 2025 | 31,250 | 113,031 | - | 22.1 | 689,688 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 35.80 per share. | 13 Nov 2025 | 26,166 | 65,341 | - | 35.8 | 936,743 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Sale of securities on an exchange or to another person at price $ 37.72 per share. | 13 Nov 2025 | 18,576 | 4,000 | - | 37.7 | 700,687 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 3,529 | 116,471 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | EVP, Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 13 Nov 2025 | 3,529 | 91,507 | - | 17.9 | 63,099 | Common Stock |
| Dianthus Therapeutics Inc | Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Simrat Randhawa | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) |